X-Chem leverages its proprietary DNA Encoded Library (DEL) platform containing over 200 billion small molecules to accelerate and support drug discovery programs. With premises in Waltham, Mass., London, Budapest, and Montréal, X-Chem has collaborated with most leading pharmaceutical companies in the world, and has partnerships with top tier biotechnology companies, academic centers and non-profit institutions throughout the US, Europe and Japan.
X-Chem was acquired by GHO Capital Opportunities (GHO), a specialist healthcare investor, in June 2020.
Freeman Clarke has a long-standing relationship with GHO, and we were engaged to audit and explore X-Chem’s IT landscape, to create a strategy and roadmap for the future, to highlight risks, and to identify new opportunities.
X-Chem has ambitious plans for the coming years, and systems and digital will be at the heart of these plans. They have proprietary custom software, complex back-office systems and reporting requirements, a growing infrastructure, and an internal IT and software development team. They needed a roadmap for growth that included all aspects of its technology, including business processes and systems, IT capabilities and the internal IT team, and the management and selection of external suppliers.
Terry Loding, COO and Head of Strategy commented:
“The Freeman Clarke team have been excellent people, and I am very pleased with the results. As experienced execs, rather than consultants, they are focused on the business issues and opportunities that matter to us. They have built on work already done by others and are shaping a new vision for our IT which will significantly contribute to the value of the business.”
Freeman Clarke is proud to be a part of the team advising our biotechnology client X-Chem, Inc. on its acquisition of two drug discovery companies IntelliSyn and AviSyn. We are looking forward to ensuring a smooth integration of the systems and processes, and to helping X-Chem with its continued success and growth.
Plain English board-level briefings focused on technology strategies to deliver competitive advantage and business success.
You can unsubscribe at any time.
Call us on 0203 020 1864 with any questions.
Co-Founder and Director